Dementia and Geriatric Cognitive Disorders · 2006 · 78 citations · 26 references
Life SciencesBiochemistryNeurologyDementiaNeurodegenerationProteomicsAlzheimer DiseaseBiomarkers Of NeurodegenerationClinical ProteomicsDementia BiomarkersProteomic BiomarkersBiomarker DetectionBiomarkersDisease ProteomicsProteomic IdentificationSerum Protein BiomarkersSerum ProteomicsTwo-dimensional ElectrophoresisTwo-dimensional Gel Electrophoresis
Many researches have been trying to find the potential biomarkers for Alzheimer's disease (AD). We hereby used the proteomics method to search for protein expression differences in the serum between AD patients and controls. We enrolled 59 AD patients and 74 age- and sex-matched controls in this study. Ten AD patients and 10 controls were selected for proteomic analysis. Apolipoprotein A-I (ApoA-I) was found to have a lower expression in the AD group by a proteomics two-dimensional gel electrophoresis study. We further measured the serum ApoA-I level which was significantly lower in the AD patients (112.29 +/- 21.33 mg/dl) in comparison to the controls (144.53 +/- 19.91 mg/dl; p < 0.0002). Lower serum ApoA-I levels might be a potential biomarker for AD.
26
Clinical diagnosis of Alzheimer's disease
Guy M. McKhann, David A. Drachman, Marshall Folstein et al. · Neurology · 1984 · 28K citations · Full text
Joanna M. Cordy, Ishrut Hussain, Colin Dingwall et al. · Proceedings of the National Academy of Sciences · 2003 · 360 citations · Full text